Cellular Immunotherapy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031F

B-cell Malignancies is the fastest growing sector, North America is the largest market

The Global Cellular Immunotherapy Market is projected to expand from USD 7.61 Billion in 2025 to USD 13.51 Billion by 2031, reflecting a compound annual growth rate of 10.04%. This specialized therapeutic modality leverages the patient's own immune system to identify and eradicate cancer cells, typically involving the extraction, genetic modification, and reinfusion of immune cells like T-cells to attack specific tumor antigens. Market expansion is propelled by the increasing incidence of oncological diseases and the rapid pace of regulatory endorsements, which have effectively shifted these therapies from experimental research into standard clinical practice. Highlighting this financial momentum, the Alliance for Regenerative Medicine reported a 30 percent increase in investment within the cell and gene therapy sector in 2024, signaling strong capital support for these innovative development pipelines.

Despite this positive growth trend, the market encounters substantial obstacles stemming from the intricate and expensive manufacturing protocols necessary for autologous therapies. The logistical complexity of sustaining a personalized, vein-to-vein supply chain introduces significant scalability issues and results in elevated treatment costs. These high price points pose a risk of restricting patient access to these life-saving interventions, potentially hindering the broader expansion and adoption of cellular immunotherapies within the global healthcare landscape.

Market Drivers

The rising global prevalence of cancer and autoimmune disorders acts as the central engine for the growth of the cellular immunotherapy market. With traditional treatment standards frequently resulting in inadequate outcomes for refractory malignancies, there is an intensified demand for immune-modulating solutions, such as CAR-T therapy, to provide durable biological remedies. This momentum is rooted in the increasing demographic weight of oncological conditions, necessitating the swift implementation of targeted cellular treatments. According to the American Cancer Society's "Cancer Facts & Figures 2025" report released in January 2025, over 2,041,900 new cancer diagnoses were projected for the United States alone. This burgeoning patient base compels biopharmaceutical developers to focus on creating scalable therapies that can address severe unmet medical needs across both hematological and solid tumor categories.

Concurrently, rapid technological progress in CAR-T and gene editing is reshaping the commercial environment, facilitating the evolution of these therapies from research pipelines into profitable, mainstream offerings. Refinements in genetic engineering and manufacturing consistency have smoothed the regulatory pathway, encouraging market adoption and revenue expansion. The financial viability of these innovations is demonstrated by the strong performance of key industry leaders; for instance, Gilead Sciences reported in their February 2025 "Fourth Quarter and Full Year 2024 Financial Results" that Cell Therapy product sales rose by 6 percent year-over-year to reach USD 2.0 billion. This commercial advancement is bolstered by a supportive regulatory framework, as highlighted by the Regulatory Affairs Professionals Society in January 2025, noting that the FDA's Center for Biologics Evaluation and Research approved 10 new biological license applications in 2024, demonstrating a dedicated effort to expedite access to novel biological therapies.

Market Challenges

The intricate manufacturing infrastructure required for autologous therapies represents a primary barrier limiting the broader growth of the Global Cellular Immunotherapy Market. Since these treatments necessitate a personalized, vein-to-vein supply chain, they require labor-intensive processing and stringent quality control measures that preclude traditional economies of scale. This logistical inflexibility leads to high costs of goods sold, resulting in elevated market prices that are difficult for many healthcare systems to support. As a result, these high costs restrict reimbursement coverage and reduce the number of patients who can afford these interventions, effectively placing a cap on the potential market volume for new industry entrants.

Furthermore, these manufacturing bottlenecks have created a market landscape where commercial success is highly concentrated rather than widely distributed. The inability to achieve efficient production scalability compels the industry to depend on a limited number of assets, which inhibits the diversification required for robust sector growth. According to the Alliance for Regenerative Medicine in 2025, approximately 75 percent of the global revenue in this field is derived from fewer than ten commercialized products. This significant revenue concentration highlights how scalability challenges directly prevent the broader market from evolving into a high-volume therapeutic landscape.

Market Trends

The integration of artificial intelligence into cell therapy discovery is fundamentally transforming research and development by optimizing the selection of cellular constructs and predicting therapeutic efficacy with greater accuracy. Developers are increasingly utilizing machine learning algorithms to process extensive biological datasets, enabling the rapid design of synthetic receptors that minimize off-target effects prior to wet-lab experimentation. This computational evolution is drastically shortening development schedules; as noted by the International Institute for Management Development in their "Future Readiness Indicator 2025" report from November 2025, incorporating AI-driven workflows can reduce the time needed to identify preclinical candidates by as much as 40 percent. By minimizing trial-and-error iterations, these technologies lower early-stage expenditures and improve the likelihood of clinical success.

Simultaneously, there is a distinct trend toward allogeneic "off-the-shelf" cell therapies designed to overcome the logistical constraints associated with first-generation autologous treatments. By leveraging healthy donor cells or induced pluripotent stem cells to establish standardized master cell banks, manufacturers can produce therapeutic doses in advance, ensuring immediate availability and facilitating true commercial scalability. This shift is gathering significant regulatory support; for example, Reprocell’s September 2025 article, "Current Landscape of FDA Stem Cell Approvals and Trials 2023-2025," highlights that Fate Therapeutics' off-the-shelf iPSC-derived CAR-T therapy for systemic lupus erythematosus received FDA RMAT designation in April 2025. As these platforms mature, they hold the promise of democratizing access by dismantling the complicated supply chains that currently hinder market expansion.

Key Market Players

• Bristol-Myers Squibb Company
• Novartis AG
• Gilead Sciences Inc.
• F. Hoffmann-La Roche Ltd.
• Merck KGaA
• GlaxoSmithKline plc
• AstraZeneca Plc
• Pfizer Inc.
• Johnson & Johnson
• Celyad

Report Scope

In this report, the Global Cellular Immunotherapy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Cellular Immunotherapy Market, by Therapy Type:

• CAR T Cell Therapy
• Dendritic Cell Therapy
• NK Cell Therapy
• TIL Therapy
• Others

Cellular Immunotherapy Market, by Indication:

• B-cell Malignancies
• Prostate Cancer
• Liver Cancer
• Renal Cell Carcinoma
• Others

Cellular Immunotherapy Market, by End-Use:

• Hospitals
• Cancer Institutes
• Others

Cellular Immunotherapy Market, by Region:

• North America
• Europe
• Asia Pacific
• South America
• Middle East & Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Cellular Immunotherapy Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.